RALEIGH, N.C., May 9, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the “Company” or “DARA”) announced today that it will advance development of its novel Phase 2 drug candidate for the treatment of neuropathic pain in patients with cancer. DARA’s decision to proceed was based on an additional in-depth analysis of Phase 2a data from a study previously reported in the October 2011 on-line edition of Journal of Pain and Symptom Management. The new analysis was conducted by an external biostatistician with extensive FDA experience.
